Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients
Microbiology Spectrum · 15.06.2023 · 11 (3)
DOI: 10.1128/spectrum.05125-22 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 15.06.2023. Verfasst von Yu-Shan Huang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Hauptthemen laut MEDLINE: HIV Infections, Coinfection. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as a maintenance therapy showed durable and high rates of viral suppression for HIV/HBV-coinfected patients, with only 5.1% and 2.2% of patients having HBV DNA of ≥20 IU/mL and HIV RNA of ≥50 copies/mL, respectively, at 96 weeks. Our study fills the data gap on the long-term clinical effectiveness of tenofovir alafenamide-containing antiretroviral therapy in people living with HIV who have HBV coinfection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
- Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan.
- School of Public Health, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- School of Public Health, Taipei Medical University, Taipei, Taiwan.
- Department of Internal Medicine, Kaohsiung Medical University and College of Medicine, Kaohsiung, Taiwan.
- Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
ORCID-Profile: Sung-Hsi Huang, Chien-Ching Hung
Förderung
- Gilead Sciences
Zitieren
APA
Huang, Y. S., Cheng, C. Y., Sun, H. Y., Cheng, S. H., Lu, P. L., Lee, C. H., Lee, Y. T., Tsai, H. C., Yang, C. J., Liu, C. E., Liou, B. H., Lin, S. P., Huang, S. H., Ho, M. W., Tang, H. J., Hung, C. C., & Taiwan HIV Study Group (2023). Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients. Microbiology Spectrum, 11(3). https://doi.org/10.1128/spectrum.05125-22
Vancouver
Huang YS, Cheng CY, Sun HY, Cheng SH, Lu PL, Lee CH, et al. Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients. Microbiology Spectrum. 2023;11(3). doi:10.1128/spectrum.05125-22
BibTeX
@article{Huang2023,
author = {Huang, Yu-Shan and Cheng, Chien-Yu and Sun, Hsin-Yun and Cheng, Shu-Hsing and Lu, Po-Liang and Lee, Chen-Hsiang and Lee, Yuan-Ti and Tsai, Hung-Chin and Yang, Chia-Jui and Liu, Chun-Eng and Liou, Bo-Huang and Lin, Shih-Ping and Huang, Sung-Hsi and Ho, Mao-Wang and Tang, Hung-Jen and Hung, Chien-Ching and Taiwan HIV Study Group, Taiwan HIV Study Group},
title = {Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients},
journal = {Microbiology Spectrum},
year = {2023},
volume = {11},
number = {3},
doi = {10.1128/spectrum.05125-22}
}
EUVIMED